Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
Rhea-AI Summary
Propanc Biopharma (Nasdaq:PPCB) highlighted emerging pancreatic cancer advances and outlined development plans for its lead asset, PRP. PRP has USFDA Orphan Drug Designation for pancreatic cancer and showed encouraging compassionate use data in terminal patients.
Propanc plans a Phase 1b first‑in‑human CTA in Australia in 2026 for 30–40 advanced solid tumor patients using weekly IV PRP at higher doses, followed by two Phase 2, 60‑patient studies in pancreatic and ovarian cancers to establish proof of concept.
Positive
- PRP holds USFDA Orphan Drug Designation for pancreatic cancer since 2017
- Compassionate use: 3 of 4 terminal pancreatic cancer patients exceeded life expectancy
- No severe or serious side effects observed in 2017 compassionate use data
- Planned Phase 1b FIH study in 30–40 advanced solid tumor patients
- Planned two Phase 2 trials with 60 patients each in pancreatic and ovarian cancers
Negative
- Pancreatic cancer survival outcomes remain limited despite recent treatment advances
- PRP development remains at planned Phase 1b/Phase 2 stages, with no completed controlled trials reported
News Market Reaction – PPCB
In the May 20 session, PPCB declined 12.22%, reflecting a significant negative market reaction. Argus tracked a trough of -20.4% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 19 | GMP manufacturing deal | Positive | -7.3% | Engaged European CDMO for GMP PRP production for planned Phase 1b FIH trial. |
| May 15 | Earnings & financing update | Positive | -7.0% | Reported Q3 2025/26 results and detailed private placement, cash and liability reductions. |
| May 13 | Reverse stock split | Neutral | -21.4% | Approved 1-for-25 reverse split to support Nasdaq bid-price compliance and growth plans. |
| Mar 24 | Research collaboration | Positive | -5.9% | Executed multi-year anti-aging and cancer research collaboration with Spanish universities. |
| Mar 12 | Preclinical PRP data | Positive | -13.6% | Announced >85% tumor inhibition for PRP and outlined 2026 Phase 1b trial plans. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent PPCB announcements—preclinical data, financing, collaborations, and corporate actions—have generally been followed by negative next-day price moves, suggesting a pattern of selling into news.
Over the last six months, Propanc has consistently highlighted progress around its lead candidate PRP. On Mar 12, 2026, it reported >85% tumor inhibition and targeted Phase 1b trials, yet shares fell. A multi‑year Spanish research collaboration followed on Mar 24, again with a negative reaction. Governance and capital structure steps, including a reverse split announced on May 13 and Q3 2025/26 results plus financing on May 15, were also sold. The May 19 CDMO agreement for GMP PRP production similarly coincided with a decline. Today’s pancreatic‑cancer‑focused development narrative fits this ongoing PRP build‑out.
Key Terms
clinical trial application regulatory
phase 1b medical
first-in-human medical
maximum tolerated dose medical
overall survival medical
chemotherapy medical
orphan drug designation regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26
MELBOURNE, Australia, May 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that the Company’s CEO, Mr. James Nathanielsz, forecasts new medical breakthroughs in the fight against pancreatic cancer over the next decade. Recent developments in treatment reflect a level of progress that has been difficult to achieve in this field. Clinical stage companies like Revolution Medicines Inc. and Erasca Inc. have demonstrated significant advancements in this field.
New clinical data from a late-stage trial targeting KRAS mutations, which are present in many pancreatic cancer cases, showed a meaningful improvement in overall survival. Patients receiving the targeted therapy lived approximately 13 months compared to about 7 months with standard treatment. For a disease where outcomes have remained largely unchanged for decades, this represents an important step forward.
At the same time, additional data from combination therapy approaches are reinforcing a broader trend. In one study, a treatment designed to improve tumor penetration and support immune response increased one year survival rates to roughly
“From a broader perspective, these findings reinforce the importance of continuing to deepen our understanding of the underlying biology that drives both growth and resistance. While these advances are encouraging, survival outcomes remain limited, and there is still significant work to be done,” said Mr. Nathanielsz. “At Propanc, we view this progress as part of a larger shift toward more biologically informed treatment strategies. Continued research into the mechanisms that support tumor persistence and recurrence will be critical in improving outcomes for patients facing this disease.”
Propanc’s lead asset, PRP, achieved Orphan Drug Designation status from the US Food and Drug Administration (USFDA) for the treatment of pancreatic cancer in 2017. Compassionate use data published in Scientific Reports, an online Nature journal, administering a once daily suppository of trypsinogen and chymotrypsinogen in a fixed combination of 8.92mg ea., resulted in 3 out of 4 patients significantly exceeding life expectancy from terminal pancreatic cancer with no severe or even serious side effects observed from treatment (2017).
The Company plans to file a Clinical Trial Application (CTA) in Australia for a Phase 1b, First-In-Human, Maximum Tolerated Dose study in 30 – 40 advanced cancer patients suffering from solid tumors using PRP in an I.V. formulation administered once weekly later this year. It will be at significantly higher doses than the compassionate use study based on non-clinical safety and tolerability data translating to a safe starting dose in humans. After Phase 1 completion, the Company plans to then undertake two, Phase 2, 60 patient studies in pancreatic and ovarian cancers to establish proof of concept for each therapeutic indication.
About Propanc Biopharma, Inc.
Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company’s lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.
More information: www.propanc.com
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the Company’s expectations regarding its market position and market opportunity, expectations and plans as to its product development, manufacturing and sales, and relations with its partners and investors, made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections regarding its business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expect,” “intend,” “plan,” “project,” “believe,” “estimate,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond the Company’s control. Forward-looking statements are not guarantees of future actions or performance. Actual results may differ materially from those in the forward-looking statements because of several factors, including, without limitation, risks and uncertainties related to market conditions, as well as those risks described under “Risk Factors” in the prospectus related to the proposed offering and those described in the Company’s filings with the SEC. The Company undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
Company:
Propanc Biopharma, Inc.
James Nathanielsz
+61-3-9882-0780
Investor Contact:
